Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited has appointed Professor Michael Barnes, a leading consultant neurologist and expert in medical cannabis, to its advisory board. This strategic move is expected to enhance Bioxyne’s operations in the UK medicinal cannabis market, leveraging Prof. Barnes’s extensive experience in medicine registration and distribution, which aligns with the company’s global expansion goals.
More about Bioxyne Limited
Bioxyne Limited operates in the medicinal cannabis industry, focusing on the development and distribution of cannabis-based medicines. The company aims to expand its presence in the UK market and leverage traditional prescriber channels for product distribution.
YTD Price Performance: -13.33%
Average Trading Volume: 3,465,707
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$60.62M
See more insights into BXN stock on TipRanks’ Stock Analysis page.